Tsuda T, Obara M, Hirano H, Gotoh S, Kubomura S, Higashi K, Kuroiwa A, Nakagawara A, Nagahara N, Shimizu K
Cancer. 1987 Aug 15;60(4):820-6. doi: 10.1002/1097-0142(19870815)60:4<820::aid-cncr2820600418>3.0.co;2-y.
Both untreated and treated primary neuroblastomas from 52 patients were analyzed to determine the correlation between the amplification of N-myc oncogene and various prognostic factors. Amplification of N-myc was observed in eight of 28 untreated cases and in 12 of 24 treated cases. As a whole, 12 of 18 tumors (67%) in Stage IV had N-myc amplification, but there were fewer cases in the unadvanced disease stage, as reported previously by others. Furthermore, the authors detected N-myc amplification in three of nine tumors in Stage IV-S, although the amplification was less than 50 copies. Analysis of progression-free survival at 24 months revealed that amplification of N-myc was associated with the worst prognosis (P less than 0.001). In the untreated group, no amplification of N-myc was detected in any of two ganglioneuromas and four ganglioneuroblastomas, whereas amplification of N-myc was observed in all two round-cell and six of 20 rosette fibrillary neuroblastomas. On the other hand, the authors detected amplification of N-myc in three of eight less differentiated ganglioneuroblastomas in the treated group and observed the worst prognosis in these three patients. The total percentage of the cases from both untreated and treated groups suggest that amplification of N-myc may occur more frequently in undifferentiated types of neuroblastomas than in less malignant types. In conclusion, the amplification of N-myc in neuroblastomas was closely associated with the worst prognosis, which was suggested by both disease stage and histologic characteristics.
对52例患者未经治疗和经治疗的原发性神经母细胞瘤进行分析，以确定N - myc癌基因扩增与各种预后因素之间的相关性。在28例未经治疗的病例中有8例观察到N - myc扩增，在24例经治疗的病例中有12例观察到N - myc扩增。总体而言，IV期的18个肿瘤中有12个（67%）存在N - myc扩增，但如其他人先前报道的那样，在疾病未进展阶段的病例较少。此外，作者在IV - S期的9个肿瘤中有3个检测到N - myc扩增，尽管扩增拷贝数少于50。对24个月无进展生存期的分析显示，N - myc扩增与最差的预后相关（P小于0.001）。在未经治疗的组中，2个神经节神经瘤和4个神经节神经母细胞瘤中均未检测到N - myc扩增，而在所有2个圆形细胞神经母细胞瘤和20个菊形团纤维状神经母细胞瘤中的6个中观察到N - myc扩增。另一方面，作者在治疗组的8个低分化神经节神经母细胞瘤中有3个检测到N - myc扩增，并观察到这3例患者的预后最差。未经治疗和治疗组病例的总百分比表明，N - myc扩增在未分化型神经母细胞瘤中可能比在恶性程度较低的类型中更频繁地发生。总之，神经母细胞瘤中N - myc扩增与最差的预后密切相关，这在疾病分期和组织学特征中均有体现。
